Physician profile
John C Hart
NPI 1780675363
$11,092.09
in general payments reported to CMS, 2019-2025
22 companies · $3,216 in 2025
The $3,216 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $168 · 2021: $374 · 2022: $2,149 · 2023: $2,132 · 2024: $1,687 · 2025: $3,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,392 · Food and Beverage: $2,587 · Entertainment: $56.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,391.96 |
| Food and Beverage | $2,586.59 |
| Entertainment | $56.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $6,168.97 | 2019-2025 | Ngenuity, Clareon, Centurion |
| Bausch & Lomb Americas INC. | $2,306.35 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Abbvie INC. | $688.65 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $356.85 | 2019-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $286.05 | 2019-2025 | Tecnis Iol |
| Allergan, INC. | $204.05 | 2019-2022 | |
| Ivantis, INC | $155.60 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $140.84 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.23 | 2019-2020 | |
| New World Medical,INC. | $101.45 | 2022-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Harrow Eye, LLC | $98.54 | 2023-2025 | Vevye, Iheezo |
| Tarsus Pharmaceuticals, INC. | $93.27 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $64.27 | 2022-2023 | |
| Optos, INC. | $56.13 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $53.57 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $38.86 | 2023-2025 | Iyuzeh |
| Dompe US, INC. | $38.82 | 2022-2024 | Oxervate |
| Eyevance Pharmaceuticals LLC | $37.81 | 2021-2022 | |
| Amgen INC. | $28.31 | 2024 | Tepezza |
| Rxsight INC | $21.85 | 2022 | |
| Horizon Therapeutics Plc | $13.96 | 2022 | |
| Aerie Pharmaceuticals, INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.